Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Politicians' Leadership Essential to Solve Industry Problems: Dr Aoki
October 30, 2006
- JACDS Probes Causes of Sales of Prescription Drugs without Prescription
October 23, 2006
- 2006 Symposium of APEC Network on Pharma Regulatory Science Held in Tokyo
October 23, 2006
- Young Patients More Likely to Be Given New Anti-Psychotics
October 23, 2006
- PFSB Plans Radical Review of PMDA to Speed Drug Approval
October 23, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 23, 2006
- REGULATORY NEWS IN BRIEF -1-
October 23, 2006
- SEMINAR
October 23, 2006
- Tohoku Univ. Researchers Apply for Patent for Vascular Function Monitoring System
October 23, 2006
- SELF-MEDICATION NEWS IN BRIEF
October 23, 2006
- JPA to Launch Data Sheet Database in Early December
October 23, 2006
- SURVEY 2 articles
October 23, 2006
- Shionogi, Hokkaido Univ. Jointly Create Drug Discovery Center
October 23, 2006
- Baxter Announces Results of PI/II Clinical Trial of Cell-Based H5N1 Vaccine
October 23, 2006
- Pulmicort Respules to Popularize Inhalant Steroids in Japan: AstraZeneca
October 23, 2006
- REGULATORY NEWS IN BRIEF -2-
October 23, 2006
- Taiho: Sales Up 2.0%, Strong Growth of TS-1, Global Business Props Up Overall Performance
October 23, 2006
- New Mechanism Leading to Development of Anticancer Drugs Discovered by AIST Researchers
October 23, 2006
- Hisamitsu: Sales Up 9.9%, Net Profits Up 10.3%
October 23, 2006
- Understanding of Public Indispensable to Utilize PGx: Prof. Tsuya
October 23, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…